Tifeglipron for diabetes mellitus, type 2

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Aug 2025: Trial registered, NCT07112872
  2. 19 Aug 2025: Trial started, NCT07112872

The trials

NCT07112872: A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes

State
Under way
Phase
Phase 2
People
330 planned
Started
19 Aug 2025
Primary completion
5 Feb 2028
Arms
Part A, Arm 3: Tifeglipron Dosing Regimen 1, Part A, Arm 4: Tifeglipron Dosing Regimen 2, Part A, Arm 5: Tifeglipron Dosing Regimen 3, Part A, Arm 6: Tifeglipron Dosing Regimen 4, Part A, Arm 7: Tifeglipron Dosing Regimen 5, Part A, Arm 8: Tifeglipron Dosing Regimen 6, Part A, Arm 9: Tifeglipron Dosing Regimen 7, Part B, Arm 2: Tifeglipron Dosing Regimen A, Part B, Arm 3: Tifeglipron Dosing Regimen B
Results
None posted
  1. 8 Aug 2025: Trial registered
  2. 19 Aug 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.